Progenics Pharma (PGNX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results
August 4, 2016 7:30 AM EDTOn July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone  Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected Between December 2016 and March 2017Licensed PSMA Antibody Technology to Bayer and Recognition of $5 Million in Upfront and Milestone RevenuePhase 3 Study Enrollment of PSMA-Targeted SPECT/CT Imaging Agent 1404 OngoingSecond Quarter 2016 RELISTOR Subcutaneous (SC) Net Sales of $15.9 MillionOn Track to Initiate Phase 2/3 Trial for PyLTM Imaging Agent and Phase 1 Trial For 1095 This Year
NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.... More
